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AR42J-B-13 (B-13) cells form hepatocyte-like (B-13/H) cells 
in response to glucocorticoid treatment. To establish its utility 
in toxicity and genotoxicity screening, cytochrome P450 (CYP) 
induction, susceptibility to toxins, and transporter gene expres-
sion were examined. Conversion to B-13/H cells resulted in expres-
sion of male-specific CYP2C11 and sensitivity to methapyrilene. 
B-13/H cells constitutively expressed CYP1A, induced expression 
in response to an aryl hydrocarbon receptor agonist, and activated 
benzo[α]pyrene to a DNA-damaging species. Functional CYP1A2 
was not expressed due to deletions in the Cyp1a2 gene. A B-13 cell 
line stably expressing the human CYP1A2 was therefore engineered 
(B-13−TR/h1A2) and the derived B-13/H cells expressed metabolically 
functional CYP1A2. Treatment with the cooked food mutagen 
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine resulted in a 
dose-dependent increase in DNA damage. B-13/H cells expressed 
constitutive androstane receptor (CAR) and induced CYP2B1 
mRNA levels in response to classical CAR activators. However, 
translation to functional CYP2B1 protein was low and increased 
minimally by CAR activator treatment. B-13/H cells expressed 
high levels of pregnane X-receptor (PXR) and induced CYP3A1 
in response to classical PXR activators. CYP3A genes were induc-
ible, functional, and activated aflatoxin B1 to a DNA-damaging 
species. All 23 major hepatic transporters were induced when B-13 
cells were converted to B-13/H cells, although in many cases, levels 
remained below those present in adult rat liver. However, bile salt 
export pump, Abcb1b, multidrug resistance-associated protein, 
and breast cancer resistance protein transporters were functional 
in B-13/H cells. These data demonstrate that the B-13 cell gener-
ates hepatocyte-like cells with functional drug metabolism and 
transporter activities, which can alone—or in a humanized form—
be used to screen for hepatotoxic and genotoxic endpoints in vitro.
Key Words: stem cell; liver; xenobiotic metabolism; cytochrome 
P450; transporters.
Hepatocytes are the primary defining cell of the liver, per-
forming the vast majority of its functions (Wallace et  al., 
2010a). Isolation and/or culture of hepatocytes are therefore 
common experimental techniques employed in the study of 
liver functions (Wallace et  al., 2010a). Several factors limit 
hepatocyte utility. Hepatocytes do not proliferate in vitro and 
therefore cannot be expanded in vitro. Furthermore, culture 
results in dedifferentiation and loss of function. Complex cul-
ture modifications can ameliorate this loss but experimentally 
introduce an array of often uncharacterized factors, which can 
complicate interpretation (Wallace et al., 2010a).
In many cases, human hepatocytes would be the ideal spe-
cies to use for most experiments related to toxicity. However, 
human liver is in short supply and is often of poor quality. In 
the absence of sufficient human hepatocytes from donor liv-
ers, the main alternative for generating human hepatocytes is 
through differentiation of human embryonic stem cells (ESCs) 
or induced pluripotent stem cells (iPSCs) (Lavon et al., 2004; 
Rashid et al., 2010; Takayama et al., 2012; Zhang et al., 2013). 
Despite significant progress over the last 12 years, it has not 
been possible to generate hepatocytes with function quanti-
tatively similar to adult human hepatocytes (Takayama et al., 
2012). Stem cell–derived hepatocytes remain in a fetal state 
and cannot progress further unless transplanted in vivo (Lavon 
et  al., 2004; Rashid et  al., 2010; Takayama et  al., 2012; Yu 
et al., 2012; Zhang et al., 2013). Because normal hepatocytes 
dedifferentiate into a fetal state in vitro (even when present 
within culture tissue slices) (Wallace et al., 2010a; Wright and 
Paine, 1992), it may be not be surprising that this barrier exists 
in stem cell–derived hepatocyte culture. In addition, a major 
hurdle to the use of ESC/iPSC-derived hepatocyte is their high 
cost of generation. As part of an European Commission–funded 
project, the cost of hepatocytes derived from iPSCs was calcu-
lated, taking into consideration the most recent research that 
compared drug metabolism activity in iPSC-derived hepato-
cytes with human hepatocytes (Takayama et  al., 2012). In 
order to obtain the hepatocytes, the iPSCs required a 4-stage 
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differentiation protocol with a variety of recombinant growth 
factors. In addition, the cells were infected with adenovirus 
directed to overexpress 2 transcription factors. Considering 
growth factors alone (without taking into account the cost of 
culture media, virus production, culture ware, and the cost of 
failures), it was calculated that the cost of generating hepato-
cytes is approximately 5 million times greater than using gluco-
corticoid and a human cell line with B-13 properties (d-LIVER 
consortium, 2012). With current technologies, it is unlikely that 
ESC- or iPSC-derived hepatocytes will be a practical solution 
in routine in vitro toxicity testing.
The B-13 cell could offer a potential route to delivering a 
cost-effective, simple solution to the production of functional 
hepatocytes in vitro. This rat pancreatic acinar-like cell line is 
readily expandable in simple culture medium and in response 
to one simple glucocorticoid hormone differentiates into non-
proliferative hepatocyte-like (B-13/H) cells (Shen et al., 2000; 
Wallace et al., 2010b). B-13 cells model a pathophysiological 
response of rodent and human acinar tissue to differentiate into 
hepatocytes both in vitro and in vivo on exposure to high levels 
of glucocorticoid (Fairhall et al., 2013b; Wallace et al., 2009, 
2010c). The cells retain a degree of biological stability in that 
they have maintained a normal karyotype in terms of the num-
ber of chromosomes per cell (although with some cytogenetic 
abnormalities); do not grow in soft agar (in contrast to tumori-
genic cells); and are able to selectively engraft into the pancreas 
and liver (Fairhall et al., 2013a). Within the liver, B-13 cells dif-
ferentiate into hepatocytes (Fairhall et al., 2013a). The intrinsic 
value of this cell line is that it offers an unlimited and reproduc-
ible supply of hepatocytes in vitro, without the requirement for 
tissue donors. Given both the simplicity and costs of a B-13 
approach to hepatocyte generation, it is likely that a human 
B-13 equivalent would have utility in both experimental studies 
(eg, toxicity screening) and clinical applications (eg, extracor-
poreal liver support).
In this paper, we demonstrate that B-13/H cells recapitu-
late the sexually dimorphic expression of cytochrome P450 
(CYP)2C11; retain CYP1-3 family induction to classic induc-
ers; and express variable levels of functional transporter expres-
sion. Stable transfection of the human CYP1A2 gene resulted 
in a transgenic cell line with active human protein that metabo-
lized a probe substrate and the progenotoxin 2-amino-1-methyl-
6-phenylimidazo(4,5-b)pyridine (PhIP) to a genotoxic product.
MATeRiAls AND MeTHoDs
PhIP was generously provided by Professor Nigel Gooderham (Imperial 
College, London, UK). All other materials were purchased from Sigma-Aldrich 
(Poole, UK) unless otherwise stated.
Cell culture. All cells were cultured in low glucose (1 g/l) Dulbecco’s 
Modified Eagle’s Medium containing 10% (vol/vol) fetal calf serum, 100 units/
ml penicillin, 100 μg/ml streptomycin, and 0.584 g/l l-glutamine. This medium 
contains cysteine (and its precursor methionine) as well as the nonessential 
amino acids glycine and glutamine and is therefore capable of supporting 
glutathione synthesis. B-13 cells (originally referred to as AR42J-B-13 cells by 
the laboratory that isolated the clone from the parent AR42J cell line; Mashima 
et al., 1996) were grown at 37°C at 5% CO
2
 in air in a humidified incubator, 
typically in 6-well plates. In some cases, B-13 cells were cultured in smaller 
culture formats up to 96-well plates dependent on the finally assay procedure. 
The B-13 cells had a doubling time of 30 ± 7.3 h and were subcultured every 
2–3 days by trypsinization or differentiated to B-13/H cells via treatment with 
10nM dexamethasone (DEX) for 14 days, with media changes every 2–3 days. 
B-13 cells expressing the tetracycline repressor were generated through trans-
fection of B-13 cells with pcDNA6/TR (Life Technologies) using effectene 
(Qiagen) as previously described (Wallace et al., 2010c) and selecting stably 
transfected B-13 cells (B-13−TR) using blastocidin at 8  μg/ml (for approxi-
mately 2 weeks), followed by a maintenance concentration of 4 µg/ml.
Rat hepatocytes were isolated essentially as previously described (Haughton 
et al., 2006) and cultured identically to B-13 cells without serum. All compounds 
were added to media from 1000-fold concentrated vehicle-solvated stocks.
For induction studies, cells were routinely dosed daily with inducing agents for 
3 days, with a media change every day. Cells were harvested on day 4 (24 h after 
the last treatment with inducer). Inducers were used at the following final con-
centrations: β-naphthoflavone (β-NF), 20μM; androstenol, 5μM; phenobarbital 
(PB), 1mM; 1,4-Bis-[2-(3,5-dichloropyridyloxy)]benzene, 3,3′,5,5′-Tetrachloro-
1,4-bis(pyridyloxy)benzene (TCPOBOP), 1.5μM; DEX, 10μM; 5-pregnen-3β-
ol-20-one-16α-carbonitrile (PCN), 2μM; bezafibrate, 250μM.
Transmission electron microscopy. Cells were suspended in 10mM EDTA 
in PBS (137mM NaCl, 2.7mM KCl, 10mM phosphate, pH 7.4), pelleted, and 
then fixed in 2% glutaraldehyde in Sorenson’s phosphate buffer (0.1M sodium 
phosphate, pH 7.2). The fixed cells were then processed and embedded in resin 
by the Newcastle University Electron Microscopy Research Service. Samples 
were viewed using a Philips CM100 transmission electron microscope.
Reverse transcriptase-PCR. TRIzol (Invitrogen, Paisley, UK) was used 
in the isolation of total RNA from tissue or cells following the manufacturer’s 
instructions. Reverse transcriptase-PCR (RT-PCR) was performed on total 
RNA essentially as previously described (Haughton et al., 2006). SYBR green 
was used for quantitative RT-PCR using a 7500 Fast Applied Biosciences ther-
mocycler. The primer sequences are given in Table  1. The drug transporter 
array (SABiosciences, Crawley, UK) was run using the RT2 First Strand Kit 
and RT2 SYBR Green qPCR Mastermix (SABiosciences) following the proto-
col recommended by the manufacturer.
Western blotting. Western blotting was performed essentially as pre-
viously described (Marek et  al., 2005). The antibodies used were goat anti-
CYP2C11 and anti-CYP1A1 (Daiichi Chemical Co., Tokyo, Japan), and mouse 
anti-CYP3A1 and anti-CYP2B1 + 2B2 (Abcam, Cambridge, UK). Detection 
was carried out using the relevant anti-IgG horseradish peroxidase (HRP)–con-
jugated secondary antibody and ECL-based chemiluminescent detection (GE 
Healthcare, Amersham, UK).
Immunocytochemistry. Immunofluorescence was carried out as previ-
ously described (Marek et  al., 2009) using rabbit anti-CYP2E1 (Abcam) or 
mouse anti-bromodeoxyuridine (BrdU) (BD Biosciences, Oxford, UK) and a 
fluorescein isothiocyanate– or HRP-conjugated secondary antibody. Slides were 
imaged using a Leica brightfield (Milton-Keynes, UK) or Zeiss fluorescence 
microscope (Cambridge, UK).
Alkoxyresorufin dealkylase assays. Ethoxyresorufin o deethylase (EROD), 
pentoxyresorufin o depentylase (PROD), and methoxyresorufine o demethy-
lase (MROD) activities were determined in cell lysates using a temperature-
controlled 96-well fluorimetric plate reader. Cell pellets were lysed in TM 
buffer (50mM Tris-HCl, 25mM MgCl
2
, pH 7.5) and 50 μl of the lysate was 
added to 100 μl of 4μM ethoxyresorufin, 20μM pentoxyresorufin, or 2μM of 
methoxyresorufin. Plates were prewarmed at 37°C for 10 min and reactions 
were initiated by addition of 50 μl of 500μM NADPH. Resorufin generated 
was determined by monitoring fluorescence (excitation at 522 nm, emission 
at 586 nm) using authentic resorufin as standard. Fluorescence was measured 
every 1–2 min at 37°C for 20 min with activities normalized to total cell protein.
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TABle 1
Primers Used for PCR
Oligo ID Primer Sequence (5′-3′) Comments
18s rRNA US CCCGAAGCGTTTACTTTGAA Will amplify 136 bp of rat 18s rRNA
DS CCCTCTTAATCATGGCCTCA
AhR US TGGCTGTGATGCCAAAGGGCAG Will amplify 100-bp fragment of rat AhR (NM_013149.2)
DS AAGCATGTCAGCGGCGTGGA
AhRNT US GGTTTGCCAGGTCGGATGAT Will amplify 219-bp fragment of rat AhRNT (NM_012780.1)
DS CCGTTCCCCTCAAGGACTTC
CAR US CTCTCCTGACAGGCCTGGGGT Will amplify 156-bp fragment of rat CAR (NM_022941.3)
DS CGAAGCTCAGCTAGCAGGCCC
CYP1A1 US TCCCTGGGGTCCTAGAGAACACTCT Will amplify 109-bp fragment of rat CYP1A1 (NM_012540.2)
DS TGTGGCTGATGTGAAGGCTGGG
hCYP1A2 US CACACCAGCCATTACAACCCTGCC Will amplify 1608-bp coding sequence of human CYP1A2 
(NM_000761.3)DS TCAGTTGATGGAGAAGCGCAGCC
gCYP1A2 US GTGGTCACTGGCATCCACACCA Will amplify 460-bp fragment of genomic rat Cyp1a2 
(NC_005107.3)DS AAGGGCAAGCCCCAGGGTCC
rCYP1A2 US CGCATTGGCTCCACACCCGT Will amplify 412-bp fragment of rat CYP1A2 (NM_012541.3)
DS TCTCCTCGCTCTTCCTGGGGA
CYP1B1 US CAGCTTTTTGCCTGTCACCC Will amplify 180-bp fragment of rat CYP1B1 (NM_012940.2)
DS ATGAAGCCGTCCTTGTCCAG
CYP2B1 US CGCATGGAGAAGGAGAAGTCGAACC Will amplify 151-bp fragment of rat CYP2B1 
(NM_001134844.1)DS CGACATGGGGGTACTTGAGCATCAG
CYP2B2 US CGCCTGTTGGAGCTGTTCTA Will amplify 151-bp fragment of rat CYP2B2 
(NM_001198676.1)DS ACTTCTCCTCTCTCATCCATGC
CYP2B3 US CCCTTCTCCATAGGAAAGCGTA Will amplify 269-bp fragment of rat CYP2B3 (NM_173294.1)
DS CCAGCAGGTCTCCCAGAATC
CYP2C11 US CTGCCATGGATCCAGTCCTAGTCC Will amplify 88-bp fragment of rat CYP2C11 (NM_019184.2)
DS TTCCCTCTCCCAAAGCTCTGTCTCC
CYP2C12 US TGTGAGCACTCCTGCATTTCAGG Will amplify 317-bp fragment of rat CYP2C12 (NM_031572.1)
DS AGAGCAAAAGTGCAAATCTCAGCGT
CYP2C6 US CTGTGACCAACCAGCTAAAGTCCAG Will amplify 82-bp fragment of rat CYP2C6 (XM_003748910.1)
DS CTCCATGCGGGCTAGGCCCT
CYP3A1/23 US TGGCCCAGTGGGGATTATGGGG Will amplify 183-bp fragment of rat CYP3A1/23 
(NM_013105.2)DS GGGACAGGTTTGCCTTTCTCTTGCC
CYP3A2 US TGGCAAGGTC-GTGATGGAAC Will amplify 72-bp fragment of rat CYP3A2 (NM_153312.2)
DS ACCAGATGTGGATGGAGATGG
CYP3A18 US GGAGGCCTGAACTGCTGAAGGAG Will amplify 166-bp fragment of rat CYP3A18 (NM_145782.1)
DS AAGGCACAGGTTTGGGTCCAGGA
CYP3A19 US GCCCTGAAAGGTTCAGCAAG Will amplify 282-bp fragment of rat CYP3A19 (NM_147206.2)
DS AGGCCATTCTACATCAAGCTCC
GAPDH US TGACATCAAGAAGGTGGTGAAG Will amplify 243 bp of rat glyceraldehyde 3 phosphate dehydro-
genase (NM_017008.3)DS TTGTCATACCAGGAAATGAGCT
GSTA2 US GCACAGACCAGAGCCATTCT Will amplify 508-bp fragment of rat GSTA2 (NM_017013.4)
DS GCAAAACATAAAGAAATTGGACAGT
GSTA3 US CACCGAGAACTCTTGATGTGT Will amplify 256-bp fragment of rat GSTA3 (NM_0.1509.2)
DS CAATCTCCACCATGGGCACT
GSTA4 US CTGCTTTTTGGCCAAGTCCC Will amplify 236-bp fragment of rat GSTA4 (NM_001106840.1)
DS GCCCTCTTCACTGCTAAAGCTA
GSTA5 US AAGACCGCCTTGGCAAAAGA Will amplify 356-bp fragment of rat GSTA5 (NM_001010921.1)
DS AACATCAGAGCCTGGATTACAAG
GSTK1 US AAGCAGCTCTTCCAGGTTCC Will amplify 458-bp fragment of at rat GSTK1 (NM_181371.2)
DS AGTCTGGCATTCAGGGTTGG
GSTM1 US AGACAGAGGAGGAGCGGATT Will amplify 417-bp fragment of rat GSTM1 (NM_017014.1)
DS CTGTGAGTGCCAGTGTAGCA
GSTM2 US AAGCACAACCTTTGTGGGGA Will amplify 377-bp fragment of rat GSTM2 (NM_177426.1)
DS ATTGGCTTGGAGAGGAAGCG
GSTM3 US GCGGACTTACTCACCCCATC Will amplify 328-bp fragment of rat GSTM3 (NM_020540.1)
DS AAGTCAGGACTGCAGCAAACT
GSTM4 US TACTCACACCGGAGGCTAGT Will amplify 498-bp fragment of rat GSTM4 (NM_001024304.1)
DS TTCACCAACGAACCACGTCT
GSTM5 US TCATGCCATCCGTATGCTCC Will amplify 309-bp fragment of rat GSTM5 (NM_172038.1)
DS TTGTAGCAGAGCCGAACCAG
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Oligo ID Primer Sequence (5′-3′) Comments
GSTM6 US GCAGCTCCGGAACTACTCTC Will amplify 498-bp fragment of rat GSTM6 (NM_001109192.1)
DS GCCCTTCAAGAACTCAGGCT
GSTO1 US GCGAGTACCTGGATGAAGCA Will amplify 242-bp fragment of rat GSTO1 (NM_001007602.1)
DS GAGCGAATTCCCACCGAAGA
GSTO2 US GTAGGATGTGAGACCAGCGG Will amplify 327-bp fragment of rat GSTO2 (NM_001012071.1)
DS AGCACTCTGGTGTTGATGGG
GSTP1 US ACGCAGCTTTGAGTCCACAC Will amplify 412-bp fragment of rat GSTP1 (NM_012577.2)
DS CAGGCAGGGCCTTCACATAG
GSTT1 US CGTGCTCGTGTGGATGAGTA Will amplify 399-bp fragment of at rat GSTT1 (NM_053293.2)
DS GTCAGCAGGTGGACAGTCTC
GSTT2 US TTTCAGTTGCGTACCGTGGA Will amplify 250-bp fragment of rat GSTT2 (NM_012796.2)
DS CAAAGGTGCCACGGATGTTG
GSTT3 US TTTGCCCAGGTGAACCCTTT Will amplify 496-bp fragment of rat GSTT3 (NM_001137643.1)
DS CCTCACCTCTTCACTTGCGT
GSTT4 US GATCACGGGTGAGGAGGTTC Will amplify 228-bp fragment of rat GSTT4 (NM_001109675.1)
DS TCCACCCGCATTCTCCATTC
GSTZ1 US AGGAGGGAACGCCATCTAGT Will amplify 238-bp fragment of rat GSTZ1 (NM_001109445.1)
DS TGTTGCCCGCCATCCTTTAT
MGST1 US ACGAGGTGTTGATGGCCTTT Will amplify 354-bp fragment of rat MGST1 (NM_134349.3)
DS GCTGAGGAAGGGGAGTCAAG
MGST2 US TTTGCTTTGCAAGTCGGACG Will amplify 236-bp fragment of rat MGST2 (NM_001106430.1)
DS GCTTCTGCATAGCCCCAGAA
PAPSS1 US CTCTCTTACCACTCGGCCTC Will amplify 313-bp fragment of rat PAPSS1 (NM_001106471.1)
DS AAGTGTAGCACGGAATGCCA
PAPSS2 US CCGTGTTACTCCCTGGATGG Will amplify 600-bp fragment of rat PAPSS2 (NM_001106375.2)
DS AAAGCCTTTGAGCGGAGTGG
PXR US GCTCCTGCTGGACCCGTTGA Will amplify 115-bp fragment of rat PXR (NM_052980.2)
DS GCCAGGGCGATCTGGGGAGAA
RXRα US TCTTCATCCCTGAGCTCTCCA Will amplify 263-bp fragment of rat RXRα (NM_012805.2)
DS TTCATGGGTGAGTTGAGCTGG
RXRβ US GACAGCTCCTCCCCAAATCC Will amplify 213-bp fragment of rat RXRβ (NM_206849.3)
DS GGAGTTAATCTGAGGGCTGC
SULT1A1 US ACACATCTGCCCCTGTCCT Will amplify 77-bp fragment of rat SULT1A1 (NM_031834.1)
DS GCATTTCGGGCAATGTAGA
SULT1B1 US CGAGATGTTATTACCTCTAAAGTTCCA Will amplify 88-bp fragment of rat SULT1B1 (NM_025513.1)
DS GAGTTTTCTTCAAGAGTTCAACACC
SULT1C2 US TCTGCCCTTGAGGTATCCAG Will amplify 90-bp fragment of rat SULT1C2 (NM_133547.4)
DS GCGGCTGTAATCTGCTCAA
SULT1C2A US TCTGCCCTTGAGGTATCCAG Will amplify 87-bp fragment of rat SULT1C2A 
(NM_001013177.2)DS CAGGGAAGAAGGTTTAGTTCCA
SULT1C3 US GGTACCCTGGGAGAATACATTG Will amplify 84-bp fragment of rat SULT1C3 (NM_031732.2)
DS CCACCATCCCTTTACATGGT
SULT1D1 US CCTCGACTGGTGAAGACACA Will amplify 87-bp fragment of rat SULT1D1 (NM_021769.1)
DS CCGTGCCACATAAATCATCTT
SULT1E1 US GAGAAATTTATGGAAGGGCAAG Will amplify 103-bp fragment of rat SULT1E1 (NM_012883.1)
DS CATAGAACATAAACAAAACACGTGAA
SULT2A1 US TGGGGTAATTCAACTCTTGTGA Will amplify 102-bp fragment of at rat SULT2A1 
(NM_131903.1)DS GATGTGCTCAAACCATGATCC
SULT2A2 US TCTTCAGTTCCAAGGCCAAG Will amplify 118-bp fragment of rat SULT2A2 
(NM_001025131.1)DS GTTCCCAGCGAGTCTGGTT
SULT2A6 US AAGACAACTCTTGCGAAGAAGC Will amplify 96-bp fragment of rat SULT2A6 (NM_012695.3)
DS GATGTGCTCAAACCATGATCC
SULT2B1 US GGTGATTTACTTGGGCCGGA Will amplify 420-bp fragment of rat SULT2B1 
(NM_001039665.1)DS CAGTCGCCACTGATCCCTTT
SULT4A1 US CGGAAGTTGCTTGGAAACAG Will amplify 60-bp fragment of rat SULT4A1 (NM_031641.1)
DS CATCTCACTCCTCGGCTCTC
SULT5A1 US CTCCAGAAGGACCTAACTTTGC Will amplify 69-bp fragment of rat SULT5A1 
(NM_001106194.1)DS AATGGTTGAGCGAGGTTCC
SULT6B1 US TCCGAGCTTTGGATGCCTTT Will amplify 608-bp fragment of rat SULT6B1 
(NM_001192017.1)DS CTGGGATTTTGCTCGCATCG
UGT1A1 US TGGCCTCTCTGGAACAAAGC Will amplify 486-bp fragment of rat UGT1A1 (NM_012683.2)
DS CTCCGGAGGCGTTGACATAG
TABle 1—Continued
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Luciferin-IPA assay. Luciferin-IPA (Promega, Southampton, UK) was 
used to determine CYP3A-mediated activities in cell lysates following the 
manufacturer’s instructions, except that NADPH was added to give a final con-
centration of 1.5mM. Results were normalized to total cell protein.
Comet assay. DNA damage was assessed by comet assays essentially as 
outlined (Jowsey et al., 2009). DNA damage, expressed as the mean olive tail 
moment, was calculated from 50 individual cells using AutoComet software 
(Tritek Corp., Summerduck, Virginia). When required, cells were pretreated 
daily for 3 days with inducers or vehicle with addition of potentially genotoxic 
compounds on day 3. After a further 24 h, cells were harvested and analyzed. 
Benzo[α]pyrene and PhIP were added from 100-fold molar concentrated stocks 
in dimethysulfoxide (DMSO), therefore their respective vehicle control was 1% 
(vol/vol) DMSO. To control for any effects on cell viability and proliferation 
(which can give false positive results), compounds were separately tested for 
cytotoxicity or DNA synthesis. Cytotoxicity was assessed by embedding cells in 
low melting point agarose, followed by lysis and a 3-min incubation in 0.4M Tris 
buffer pH 7.0 and staining with SYBR gold (Invitrogen) as described by Mosesso 
et al. (2012). DNA synthesis was assessed using BrdU incorporation into DNA 
with staining carried out essentially as described in Mosesso et al. (2012).
Transporter efflux assays. Efflux transporter function was determined 
by loading cells with 5μM cholyl-lysyl-fluorescein (CLF) obtained from BD 
Biosciences, 1μM Hoechst 33342, or 1μM 5-chloromethylfluorescein diac-
etate (CMFDA) for 30 min as per standard culture. Cells were then washed 
in PBS and incubated with a transporter inhibitor (100μM troglitazone, 5μM 
cyclosporine A, 1μM KO143, or 10μM MK571) or vehicles for 30 min as per 
standard culture. After 3 washes in PBS, levels of fluorophore retained within 
the cells were determined using the following fluorimetric settings: CLF, exci-
tation at 490 nm, emission at 550 nm; Hoechst 33342, excitation at 355 nm, 
emission at 480 nm; and CMFDA, excitation at 480 nm, emission at 520 nm.
Genomic sequencing of B-13 cells. B-13 cells were expanded in ten 
75-cm2 culture flasks and the medium removed (and confirmed negative for 
bacterial and mycoplasma contamination) prior to DNA isolation as previously 
outlined (Wallace et  al., 2010c). The DNA was then subjected to mate-pair 
library construction and SOLiD Whole Genome sequencing (Becton Coulter 
Genomics), sequencing at 30× coverage of a haploid rat genome. The SOLiD 
color space raw data were mapped to the reference Wistar rat genome sequence 
(RN4) using the Corona Lite platform (v 4.2.1) from Applied Biosystems. 
A maximum of 4 mismatches per 50-bp read were allowed in the mapping step. 
The pairing pipeline of Corona was used to correctly match mate pairs mapped 
to the reference (assuming a fragment size distribution of 260–2160 bp, deter-
mined from a sample of the correctly matched reads). The single nucleotide 
polymorphism, small InDel, and large InDel pipelines used the results of these 
procedures to find variants in the mapped reads compared with the reference. 
These variants were then interrogated using the Integrative Genomic Viewer 
software (Robinson et  al., 2011; Thorvaldsdóttir et  al., 2013) available at 
https://www.broadinstitute.org/igv/ and by alignment with the reference Wistar 
rat genome sequence RN4.
hCYP1A2 cloning. The full-length coding sequence of the human CYP1A2 
gene (hCYP1A2) was amplified from cDNA prepared from donor liver samples. 
Human liver tissue was obtained with informed consent from patients undergo-
ing surgical liver resections at the Freeman Hospital, Newcastle, with ethical 
approval from the Newcastle and North Tyneside 1 Ethics Research Committee 
(NRES—The Newcastle Hepatopancreatobiliary Research Tissue Bank—10/
H0906/41). PCR products were separated by agarose gel electrophoresis and 
extracted using a gel extraction kit (Qiagen, Manchester, UK). The extracted 
DNA was cloned into a pENTR/D-TOPO vector (Invitrogen) and transformed 
into TOP10 competent cells (Invitrogen) following the manufacturer’s protocol. 
Plasmid DNA was purified using Spin minipreps kits (Qiagen) and plasmid con-
taining the CYP1A2*1 (wild-type hCYP1A2) cDNA transferred to a pT-Rex-
DEST30 vector (Invitrogen) using LR Clonase II (Invitrogen) following the 
recommended protocol prior to transfection into B-13−TR cells using effectene as 
previously described (Wallace et al., 2010c). Stable transfectants were selected 
using geneticin and blastocidin (both Invitrogen) at 400 and 8 μg/ml, respec-
tively, for 2 weeks to generate cell lines expressing both the tetracycline repressor 
and hCYP1A2 (B-13−TR/h1A2). B-13−TR/h1A2 were routinely maintained in culture 
medium supplemented with 250 μg/ml geneticin and 4 μg/ml blastocidin.
Statistics. The student’s 2-tailed t test was used to determine significant 
difference between groups. Significance was achieved where p < .05. For 
comet assays, statistical significance was tested using ANOVA and significance 
between groups tested using the Bonferroni-Holm ad hoc test.
ResUlTs
B-13/H Cells Express an Hepatic Phenotype and Male 
Pattern of CYP Expression
Figure 1A demonstrates that the B-13 cells used in these stud-
ies formed hepatocyte-like B-13/H cells after treatment with 
10nM DEX for 14  days. The alteration from B-13 to B-13/H 
phenotype was characterized by a reduction in proliferation and 
Oligo ID Primer Sequence (5′-3′) Comments
UGT1A3 US TATGGCTCTCTGGCGAGACT Will amplify 347-bp fragment of rat UGT1A3 (NM_201424.2)
DS GGTCTAGTTCCGGTGTAGCG
UGT1A5 US GACTCCATGTGACCCTGCAA Will amplify 461-bp fragment of rat UGT1A5 
(NM_001039549.1)DS CCCACACGGAATCACAGGAT
UGT1A8 US AGAGGTGAGTTGGCACATGG Will amplify 343-bp fragment of rat UGT1A8 (NM_175846.2)
DS TGGCAAAATATTCCCCCGCT
UGT1A9 US CCATCAATAATTTTTGCCAAAGACA Will amplify 393-bp fragment of rat UGT1A9 (NM_201425.2)
DS GGAGGCGTTGACATAGGCTT
UGT2B1 US GCAAAGCACTCATTTGGAACAAG Will amplify 415-bp fragment of rat UGT2B1 (NM_173295.1)
DS TCCAAGTCCCAGAAGGTTCG
UGT2B2 US TCGACTTTTGGTTCGAGAGACTT Will amplify 317-bp fragment of rat UGT2B2 (NM_031533.5)
DS TGCAATTGCGTTGGCCTTTT
UGT2B3 US CCTGCTACAGATAAGTTGCTGTTTC Will amplify 380-bp fragment of rat UGT2B3 (NM_153314.2)
DS GCTGCTTGTTTGAAACGGTGT
Abbreviation: RXR, retinoid X-receptor.
TABle 1—Continued
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Donor-Free Cells For ToxiCiTy sCreening
Fig. 1. B-13 cells differentiate to hepatocyte-like B-13/H cells and express a male pattern of CYP. A, Representative brightfield (×100) and electron 
photomicrographs (×3400) of B-13 and B-13/H cells. B, Western blot (upper panels) and immunocytochemical staining for CYP2E1 in B-13 and B-13/H 
cells. For the Western blot, each lane contains 20 µg cell protein/lane. Data typical of at least 50 separate experiments. C, RT-PCR for the indicated tran-
scripts, ♂, male-predominant form, ♀, female-predominant form. Data typical of at least 5 separate experiments. D, Western blot for CYP2C11 in the indi-
cated extracts. Each lane contains 20 µg protein/lane. Data typical of at least 4 separate experiments. E, Quantitative RT-PCR for CYP2C11 and CYP2C12; 
* indicates statistical significantly different from male rat liver. Data are the mean and SD of 3 separate determinations from the same experiment, typical of 
at least 3 separate experiments. F, Toxicity of methapyrilene in B-13 and B-13/H cells after treatment for 24 h with viability assessed by trypan blue exclu-
sion. Data are the mean and SD of 3 separate samples from the same experiment, typical of 3 separate experiments. Abbreviations: CYP, cytochrome P450; 
RT-PCR, reverse transcriptase-PCR.
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an increase in cell size as previously observed (Wallace et al., 
2010b). Ultrastructural analysis by transmission electron micros-
copy demonstrated that there was an increase in the cytoplasmic 
ratio and a significant increase in the number of mitochondria 
(Fig. 1A) from 5 ± 2 to 38 ± 20 mitochondrion/cell in randomly 
selected B-13 and B-13/H cells, respectively. Figure 1B further 
shows that there were rat hepatocyte levels of CYP2E1 expres-
sion in B-13/H cells induced from undetectable levels in B-13 
cells. CYP2E1 was present in 95%–100% of B-13/H cells as 
determined by immunohistochemical analysis (Fig. 1B). These 
data are typical of the response of B-13 cells to exposure to 
10nM DEX and these endpoints were used throughout the fol-
lowing studies to confirm differentiation to B-13/H cells.
Cytogenetic and fluorescent in situ hybridization studies have 
established that B-13 cells are rat cells and were derived from a 
male rat because all cells contain Y chromosomes (Fairhall et al., 
2013a). Because several rodent hepatic CYPs are expressed in 
a sexually dimorphic pattern (Morgan et  al., 1985; Waxman 
and Holloway, 2009), the expression of the major hepatic CYP 
forms was therefore examined. Figure 1C indicates that B-13 
cells did not express detectable levels of the major hepatic male 
or female CYP2C11 and CYP2C12 mRNA transcripts, respec-
tively, whereas in the B-13/H phenotype, the CYP2C11 mRNA 
transcript was expressed, but not the CYP2C12.
Quantitative RT-PCR suggests that B-13/H cells expressed 
approximately 10% of the CYP2C11 mRNA levels found in adult 
male rat liver and 0.1% of the CYP2C12 mRNA levels found in 
female rat liver (Fig. 1D). CYP2C6 is a related CYP2C form that 
does not show a sexually dimorphic pattern of expression (Morgan 
et al., 1985; Waxman and Holloway, 2009). Figure 1C shows that 
this gene was expressed in B-13/H cells from undetectable levels 
in B-13 cells. Quantitative RT-PCR indicated CYP2C6 mRNA 
was induced > 300-fold in B-13/H cells (data not shown). Western 
blotting for CYP2C proteins essentially supports the transcript 
data. Figure 1D indicates that there was no detectable CYP2C 
protein in B-13 cells, whereas B-13/H cells expressed immunode-
tectable protein at similar levels to those present in male rat liver. 
To establish whether the CYP2C11 expressed in B-13/H cells was 
functional, B-13 and B-13/H cells were treated with methapy-
rilene, which has been shown to be activated to a toxic product by 
CYP2C11 (Ratra et al., 1998). Figure 1F shows that the viability 
of B-13 cells was unaffected by methapyrilene exposure at con-
centrations of up to at least 500µM, whereas methapyrilene treat-
ment caused a dose-dependent loss of viability in B-13/H cells, 
with an EC
50%
 concentration of approximately 20µM.
The Aryl Hydrocarbon Receptor Activator β-NF Induces 
CYP1A1 Expression in B-13 and B-13/H Cells and 
Sensitizes Cells to the Genotoxic Effects of Benzo[α]pyrene
The CYP1A subfamily is of toxicological significance due to 
its metabolism of a range of carcinogens such as polyaromatic 
hydrocarbons (CYP1A1) and heterocyclic amines (CYP1A2) 
(Conney, 1982; Ma and Lu, 2007). These genes are induc-
ible through their regulation by the aryl hydrocarbon receptor 
(AhR) (Nebert et  al., 2004). Figure  2A shows that both B-13 
and B-13/H cells expressed the AhR and its heterodimeric part-
ner AhR nuclear translocator mRNA transcripts. The cells also 
expressed CYP1A1 mRNA although CYP1A2 was not detect-
able in either B-13 or B-13/H cells. Interestingly, the related 
CYP1B1 mRNA transcript—often expressed at high levels in 
tumor cells (McFadyen and Murray, 2005)—was expressed in 
B-13 cells but downregulated to near hepatocyte levels in B-13/H 
cells (Fig. 2A). Quantitative RT-PCR confirmed that CYP1A1 
mRNA expression was approximately 10-fold higher in B-13/H 
cells versus B-13 cells. Both B-13 and B-13/H cells induced their 
levels of CYP1A1 mRNA levels significantly by approximately 
100-fold in response to exposure to β-NF (Fig. 2B). In contrast, 
nuclear receptor activators that regulate induction of other major 
hepatic CYP subfamilies (andostenol, PB, and TCPOBOP acti-
vate the constitutive androstane receptor [CAR; Qatanani and 
Moore, 2005]; DEX [at 10µM] and PCN activate the pregnane 
X-receptor [PXR; Kliewer et  al., 1999]; bezafibrate activates 
the peroxisome proliferator-activated receptor α [Kliewer et al., 
1999]) had no significant effect on CYP1A1 mRNA levels, with 
the exception of DEX at 10µM (although a similar response was 
seen in rat hepatocytes treated with this high concentration of 
DEX; Supplementary Figure 1).
Figure 2C indicates that the levels of CYP1A1 protein were 
relatively low in both untreated B-13 and B-13/H cells but that 
β-NF treatment induced a similar level of expression of CYP1A1 
to that seen in β-NF-treated rat hepatocytes. These data were con-
firmed at the level of enzyme activity using EROD as a CYP1A1 
probe substrate (Fig. 2D). The specific levels of EROD activity 
after treatment with β-NF as well as other nuclear receptor activa-
tors in B-13/H cells in particular showed both a quantitative and 
qualitative similarity to activities observed with rat hepatocytes. 
Although the fold induction in EROD activity after treatment 
with β-NF was relatively low (maximum 2.5-fold) compared 
with both fold changes at the level of mRNA and protein, this 
was likely due to metabolism of the substrate by other enzymes 
in noninduced cells because rat hepatocytes give similar levels of 
activity in both untreated and β-NF-treated cells. This conclusion 
is supported by the observation that the CYP1A1-activated pro-
carcinogen benzo[α]pyrene did not give rise to detectable levels 
of DNA damage in noninduced B-13 or B-13/H cells (Fig. 2E). 
However, in both B-13 and B-13/H cells, benzo[α]pyrene treat-
ment resulted in a dose-dependent increase in DNA damage 
(detectable at 100µM, the highest concentration examined), with 
β-NF pretreatment resulting in increased sensitivity in B-13/H 
cells (DNA damage detectable by 25µM). This latter observation 
of increased sensitivity to benzo[α]pyrene-dependent DNA dam-
age by B-13/H cells was likely due to the more robust induction of 
EROD activity compared with B-13 cells (Fig. 2D). In all cases, 
the increase in the appearance of comets with benzo[α]pyrene 
treatment in B-13/H was associated with direct damage to the 
DNA. At the concentration range of benzo[α]pyrene employed, 
comets were not associated with cytotoxicity or with a significant 
increase in DNA synthesis (Supplementary Figure 2).
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Fig. 2. B-13/H cells express the AhR, induce functional CYP1A1 in response to challenge with an AhR agonist, and activate benzo[α]pyrene to a DNA-
damaging species. A, RT-PCR for AhR and CYP1-related transcripts. Results typical of at least 5 separate experiments. B, Quantitative RT-PCR for the CYP1A1 
transcript in B-13 and B-13/H cells after treatment with inducers as outlined in Materials and Methods section. Data are the mean and SD of 3 separate samples 
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Stable Transfection of Functional Human CYP1A2 into 
B-13 Cells Sensitizes B-13/H Cells to the DNA-Damaging 
Effects of the Cooked Food Mutagen PhIP
Because both B-13 and B-13/H cells failed to express any 
detectable CYP1A2 mRNA (Fig. 2A), proteins from B-13 and 
B-13/H cells were examined by Western blotting under chroma-
tographic conditions that separate the closely related CYP1A1 
and CYP1A2 proteins. Figure 3A suggests that although B-13 
cells, B-13/H cells, and rat hepatocytes induced readily detect-
able levels of CYP1A1 protein in response to treatment with β-
NF, only rat hepatocytes induced expression of CYP1A2 protein.
To establish whether the Cyp1a2 genes are disrupted in B-13 
cells, B-13 DNA was sequenced as outlined in the Materials 
and Methods section and aligned to the reference rat genome 
sequence. This analysis indicated that the B-13 genome was 
disrupted at the 5′ end of the Cyp1a2 gene such that the proxi-
mal promoter, first (noncoding) exon, first intron, and part of 
the coding second exon (including the translation start site) 
were deleted (Fig.  3B). To confirm that all B-13 Cyp1a2 
alleles were disrupted, the region around the predicted dele-
tion region was analyzed by PCR. Figure 3C suggests that no 
functional Cyp1a2 gene is present in the B-13 cells because 
primers designed to amplify a genomic region at the 3′ end of 
the predicted deleted region failed to amplify a fragment from 
DNA isolated from B-13 DNA. In contrast, a fragment of the 
predicted size was amplified when Wistar rat DNA was used 
as template.
The human CYP1A2 cDNA sequence was therefore cloned as 
outlined in the Materials and Methods section and stably trans-
fected into B-13−TR cells expressing the doxycycline-regulated 
transcription factor to form B-13−TR/h1A2 cells. Figure 3D shows 
that the human CYP1A2 mRNA and protein were expressed in 
B-13−TR/h1A2 cells but not in the parent B-13 cell line. Doxycyclin 
treatment increased the expression of human CYP1A2 in B-13−
TR/h1A2 cells; however, full repression of the transgene in the 
absence of doxycycline was not apparent (Fig. 3D).
To determine whether the hCYP1A2 protein was meta-
bolically functional, cells were examined for their ability to 
metabolize methoxyresorufin. The effect of furafylline was also 
examined because this is a specific inhibitor of human CYP1A2 
(Sesardic et al., 1990). Figure 3E demonstrates that the parent 
B-13 possessed undetectable levels of MROD activity and on 
differentiation to B-13/H cells, MROD activity was not inhibita-
ble by furafylline. In contrast, B-13−TR/h1A2 cells expressed low 
but detectable (and furafylline-inhibitable) levels of MROD 
activity. Conversion of these cells to a B-13−TR/h1A2/H phenotype 
(by treatment with 10nM DEX for 14 days) resulted in high lev-
els of furafylline-inhibitable MROD activity. The effects of dox-
ycyclin on transgene expression were minimal likely because of 
a leaky high constitutive expression of the transgene.
Figure 3F shows that treating parent B-13 cells or B-13−TR/
h1A2 cells with up to 200µM PhIP did not result in any appre-
ciable DNA damage. However, addition of PhIP to B-13/H 
or B-13−TR/h1A2/H cells resulted in a dose-response increase in 
DNA damage, with B-13−TR/h1A2/H cells showing significantly 
greater damage at 25–100µM PhIP compared with B-13/H 
cells. Doxycyclin treatment had little effect on the level of 
DNA damage, due to leaky expression of the transgene in cells 
treated with doxycyclin. This increase in the appearance of 
comets with PhIP treatment in B-13/H and B-13−TR/h1A2/H cells 
was associated with direct damage to the DNA. At the con-
centration range employed, comets were not associated with 
cytotoxicity or with a significant increase in DNA synthesis 
(Supplementary Figure 2).
CAR Activators Induce CYP2B1 mRNA in B-13/H Cells
The CYP2B subfamily of CYPs were some of the first 
CYPs to be purified to homogeneity and shown to be markedly 
induced by PB pretreatment. Although it has been established 
that CAR mediates this induction, PB does not bind directly 
to the CAR. The mechanism has recently been determined to 
be associated with an interference in epidermal growth factor 
(EGF) signaling (Mutoh et al., 2013).
Figure  4A indicates that CAR mRNA was undetectable 
in B-13 cells, but detectable in B-13/H cells. Because only 
CYP2B1 mRNA was detectable in B-13/H cells, the expres-
sion of this CYP2B gene was examined after treatment with 
a variety of CYP inducers. B-13 cells did not respond to any 
inducer and CYP2B gene expression at the mRNA level was 
not detectable (data not shown). In contrast, Figure 4B demon-
strates that the CAR activators PB and TCPOBOP induced at 
least a 24-fold increase in CYP2B1 mRNA expression. High 
concentrations of DEX also induced CYP2B1, likely through 
activation of the PXR (Lim and Huang, 2008). The mouse 
CARβ inverse agonist androstenol did not induce CYP2B1 
mRNA (Fig. 4B). Supplementary Figure 3 indicates a qualita-
tively similar CYP2B1 mRNA induction response to CAR acti-
vators in primary hepatocytes; however, the relative levels of 
CYP2B1 mRNA remained below those present in untreated rat 
liver, whereas B-13/H cells induced their levels above untreated 
from the same experiment, typical of 3 separate experiments. *Statistically different from the same cell type treated with vehicle alone. C, Western blot for CYP1A1 
following vehicle or β-NF treatment as outlined in Materials and Methods section, each lane contains 20 µg cell protein/lane. Data are typical of at least 3 separate 
experiments. D, EROD activity in B-13, B-13/H, and hepatocytes following the treatment with inducers as outlined in Materials and Methods section. Data are the 
mean and SD of 3 separate samples from the same experiment, typical of 3 separate experiments. *Statistically different from the same cell type treated with vehi-
cle alone. E, Comet assay (olive tail moment) in response to benzo[α]pyrene exposure in B-13 and B-13/H cells after pretreatment with vehicle or the CYP1A1 
inducer β-NF. *Significantly different from vehicle-only-treated cells. Abbreviations: AhR, aryl hydrocarbon receptor; AhRNT, AhR nuclear translocator; β-NF, 
β-naphthoflavone; CYP, cytochrome P450; DEX, dexamethasone; EROD, ethoxyresorufin o deethylase; PB, phenobarbital; PCN, 5-pregnen-3β-ol-20-one-16α-
carbonitrile; RT-PCR, reverse transcriptase-PCR; TCPOBOP, 1,4-Bis-[2-(3,5-dichloropyridyloxy)]benzene, 3,3′,5,5′-Tetrachloro-1,4-bis(pyridyloxy)benzene.
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Fig. 3. B-13−TR/h1A2 (humanized) cells express functional hCYP1A2, which activates PhIP to a DNA-damaging species. A, Western blot for CYP1A1 and 
CYP1A2 after treatment with β-NF inducer as indicated. Each lane contains 20 µg cell protein/lane. B, Schematic diagram of B-13 CYP1A2 genomic region indi-
cating deletion and position of genomic primer hybridization used in PCR amplification. C, PCR using genomic DNA from the indicated source and gCyp1a2US 
and gCyp1a2DS primers. D, RT-PCR for human CYP1A2 (upper panels) and Western blot (lower panels) for CYP1A1 and CYP1A2 in B-13 and B-13−TR/h1A2 with 
or without doxycycline treatment (2 μg/ml). Data typical of 3 separate experiments. E, MROD assay in B-13 and B-13−TR/h1A2 with or without addition of furafyl-
line (100μM). Data are mean and SD of 3 separate determinations from the same experiment, typical of 3 separate experiments; *statistically significantly activity 
compared with extract without addition of furafylline, $statistically significant different activity compared with respective B-13 equivalent, †statistically significant 
different activity compared with parent B-13 cells. F, Comet assay (olive tail moment) with B-13 or B-13−TR/h1A2 in response to PhIP exposure with or without doxy-
cycline treatment. * indicates significantly different. Abbreviations: β-NF, β-naphthoflavone; CYP, cytochrome P450; HLM, human liver microsomes; MROD, 
methoxyresorufine o demethylase; PhIP, 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; RT-PCR, reverse transcriptase-PCR.
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Fig. 4. B-13/H cells express the CAR and robustly induce CYP2B1 mRNA in response to CAR activators, but expresses limited functional CYP2B1 protein. 
A, RT-PCR for the indicated transcripts. Data typical of 3 separate experiments. B, Quantitative RT-PCR for CYP2B1 mRNA in B-13 and B-13/H cells in response 
to indicated inducer treatments. Data are mean and SD of 3 separate determinations from the same experiment, typical of 3 separate experiments. *Statistically dif-
ferent from vehicle-only-treated cells. C, Western blot for CYP2B1 in B-13 cells, B-13/H cells, or hepatocytes treated with inducing concentrations of TCPOBOP 
or PB as outlined in Materials and Methods section, each lane contains 20 µg cell protein/lane. Data are typical of at least 3 separate experiments. D, PROD 
activity in B-13 cells and B-13/H cells treated with the indicated inducers. Data are mean and SD of 3 separate determinations from the same experiment, typi-
cal of 2 separate experiments. *Statistically different from the same cell type treated with vehicle alone. E, Comet assay (olive tail moments) in response to 
cyclophosphamide exposure in B-13 and B-13/H cells pretreated with or without PB. *Significantly different from vehicle-only-treated cells. Abbreviations: 
β-NF, β-naphthoflavone; CAR, constitutive androstane receptor; CYP, cytochrome P450; DEX, dexamethasone; PB, phenobarbital; PCN, 5-pregnen-3β-ol-20-
one-16α-carbonitrile; PROD, pentoxyresorufin o depentylase; RT-PCR, reverse transcriptase-PCR; TCPOBOP, 1,4-Bis-[2-(3,5-dichloropyridyloxy)]benzene, 
3,3′,5,5′-Tetrachloro-1,4-bis(pyridyloxy)benzene.
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liver levels. Despite this robust induction of CYP2B1 mRNA in 
B-13/H after treatment with CAR activators, B-13/H cells did 
not express detectable levels of CYP2B protein (Fig. 4C) and 
there was a relatively low fold increase in CYP2B-mediated 
PROD activity in cell extracts (Fig. 4D).
Figure  4E shows that DNA damage caused by cyclophos-
phamide (which is metabolized by CYP2B to a genotoxic 
metabolite) was only apparent after treatment with 200µM 
cyclophosphamide in B-13/H cells, but not in B-13 cells. PB 
pretreatment did not significantly increase cyclophosphamide-
dependent DNA damage in B-13/H cells, confirming that 
translation of CYP2B1 mRNA into functional protein limited 
functional CYP2B1 induction in B-13/H cells. The increase in 
the appearance of comets with cyclophosphamide treatment in 
B-13/H cells was however associated with direct damage to the 
DNA. At the concentration range employed, comets were not 
associated with cytotoxicity or with a significant increase in 
DNA synthesis (Supplementary Figure 2).
PXR Activators Induce a Quantitatively Liver Equivalent 
Induction of CYP3A1 in B-13/H Cells
The CYP3A subfamily is constitutively expressed and forms 
a major expressed subfamily in adult rat liver. The orthologous 
subfamily in man includes the major expressed gene CYP3A4, 
which is responsible for the metabolism of approximately 50% 
of drugs. Both CYP3A4 in man and CYP3A1 (also referred to 
as CYP3A23) in the rat are induced by activators of the PXR 
(Kliewer et al., 2002).
Figure  5A demonstrates that B-13/H cells—but not B-13 
cells—expressed PXR mRNA as well as CYP3A1 and sev-
eral other CYP3A transcripts. Figure 5B demonstrates that the 
PXR activators PB, DEX (at 10µM), and PCN induced up to 
approximately a 160-fold increase in CYP3A1 mRNA, to lev-
els greater than found in intact adult rat liver. TCPOBOP also 
induced a lower fold increase in CYP3A1 mRNA (Fig. 5B) but 
did not give rise to an increase in CYP3A1 protein (data not 
shown). B-13 cells failed to induce detectable levels of CYP3A 
mRNAs after treatment with any inducer (data not shown).
A similar qualitative induction response to these inducers 
was also observed in primary hepatocytes (Supplementary 
Figure 4). When comparing with the levels of CYP3A1 pro-
tein induced by the most potent inducers—DEX (at 10µM) and 
PCN—similar levels of protein were expressed by B-13/H cells 
and primary hepatocytes (Fig. 5C). Despite significant increases 
in CYP3A1 mRNA over vehicle control, β-NF, PB, TCPOBOP, 
and bezafibrate failed to induce an increase in CYP3A1 protein 
(data not shown).
Figure 5D indicates that—in contrast to CYP2B induction—
DEX (at 10µM) and PCN treatment resulted in the induction of 
functionally active CYP3A protein in B-13/H cells. To test this 
observation, B-13 and B-13/H cells were exposed to the pro-
carcinogen aflatoxin B1, which is metabolized to a genotoxic 
product by CYP3A enzymes (Kelly et  al., 1997; Yamazaki 
et al., 1995). Figure 5E shows that aflatoxin B1 did not cause 
DNA damage in B-13 cells or B-13 cells pretreated with PCN. 
In DEX inducer (ie, 10µM) pretreated B-13 cells, aflatoxin B1 
exposure resulted in a dose-dependent increase in DNA dam-
age, likely due to a glucocorticoid receptor–dependent promo-
tion of B-13/H phenotype and subsequent induction of CYP3A1 
expression within the short period of induction. Figure 5E also 
indicates that DNA damage was detectable in untreated B-13/H 
cells at 400nM aflatoxin B1. Pretreatment with DEX (at 10µM) 
resulted in a readily detectable dose-response increase in DNA 
damage, detectable at 100nM aflatoxin B1 (the lowest concen-
tration examined). PCN pretreatment resulted in a less marked 
increase in DNA damage in response to aflatoxin B1 (Fig. 5E). 
This is likely due, in part, to a less robust induction of functional 
CYP3A (Fig. 5D). However, it is likely that other unknown fac-
tors may be involved.
The increase in DNA damage with aflatoxin B1 in B-13/H 
cells was likely associated with direct damage to the DNA. At 
the concentration range employed, comets were not associated 
with cytotoxicity or with a significant increase in DNA synthe-
sis (Supplementary Figure 2).
Expression of Phase II Genes in B-13 Cells
Because the toxicity of many chemicals is affected by the 
activity of phase II enzyme systems, the expression of sul-
fotransferases (SULTs), glucuronyltransferases (UDPGTs), and 
glutathione S transferases (GSTs) was examined by RT-PCR. 
Figure 6 demonstrates that, in general, there is an upregulation 
in the expression of these genes in B-13/H compared with B-13 
cells. B-13/H cells expressed 5 (from a total of 14) SULTs, 5 
(from a total of 8 hepatic) UDPGTs, and 15 (from a total of 
21) GSTs (Fig. 6).
B-13/H Cells Are Resistant to Proliferation In Vitro
To establish whether B-13/H cells may be suitable for 
screening chemicals for clastogenicity, B-13 and B-13/H 
cells were examined for evidence of cell proliferation 
through incorporation of BrdU (because detection of clas-
togenicity is dependent on active mitosis in cells exposed to 
clastogenic chemicals). Note that genomic sequencing indi-
cated that both the K-ras and p53 genes were free of nonsyn-
onymous mutations (Supplementary Figure 5A). The K-ras 
gene contains an insertion and a deletion in the proximal pro-
moter and intronic region, respectively, which may account 
for relatively high levels of expression of K-ras in B-13 and 
B-13/H cells, in contrast to p53 levels that appear to be low 
(Supplementary Figures 5B and 5C). However, genomic 
sequencing suggests that the relatively high expression of 
K-ras will be of a normal wild-type protein product. Figure 7 
demonstrates that BrdU is incorporated extensively into B-13 
nuclei, with 60% showing evidence of active DNA synthe-
sis. In contrast, B-13/H cells did not incorporate BrdU into 
their nuclei, suggesting that the cells enter replicative senes-
cence under standard culture conditions. A number of growth 
factors have been examined for their ability to modulate 
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Fig. 5. B-13/H cells express the PXR and robustly induce CYP3A1 mRNA, protein, and activity in response to PXR activators. A, RT-PCR for the indi-
cated transcripts, data typical of 6 separate experiments. B, Quantitative RT-PCR for CYP3A1 mRNA in B-13 and B-13/H cells in response to indicated inducer 
treatments. Data are mean and SD of 3 separate determinations from the same experiment, typical of 3 separate experiments. *Significantly different from 
vehicle-only-treated cells. C, Western blot for CYP3A1 in B-13 cells, B-13/H cells, or hepatocytes treated with inducing concentrations of DEX or PCN as out-
lined in Materials and Methods section, each lane contains 20 µg cell protein/lane. Data typical of 3 separate experiments. D, CYP3A1 activity assessed by the 
luciferin-IPA assay in the indicated cell types following treatment with inducers as outlined in Materials and Methods section. Data are mean and SD of 3 separate 
determinations from the same experiment, typical of 3 separate experiments. *Significantly different from vehicle-only-treated cells. E, Comet assay (olive tail 
moment) in response to aflatoxin B1 exposure in B-13 and B-13/H cells pretreated with or without inducing concentrations of DEX or PCN. *Significantly differ-
ent from vehicle-only-treated cells. Abbreviations: β-NF, β-naphthoflavone; CYP, cytochrome P450; DEX, dexamethasone; PB, phenobarbital; PCN, 5-pregnen-
3β-ol-20-one-16α-carbonitrile; PXR, pregnane X-receptor; RT-PCR, reverse transcriptase-PCR; TCPOBOP, 1,4-Bis-[2-(3,5-dichloropyridyloxy)]benzene, 
3,3′,5,5′-Tetrachloro-1,4-bis(pyridyloxy)benzene.
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B-13 cell behavior under serum-free conditions with EGF 
demonstrating the most potent activity in terms of B-13 
proliferation and cell signaling activity (unpublished data). 
Figure 7 further shows, however, that EGF failed to stimulate 
B-13/H DNA synthesis (and similar results were seen with 
a variety of other hepatocyte mitogens—data not included). 
Interestingly, EGF treatment altered the phenotype of B-13 
cells and potently stimulated DNA synthesis in a minority 
of cells, supporting our unpublished observations that B-13 
cells are responsive to EGF. Despite this response in a limited 
number of cells, overall EGF reduced the proportion of B-13 
cells actively undergoing DNA synthesis (Fig. 7B).
B-13 Cells Upregulate Transporter Expression and Are 
Functional in B-13/H Cells
Drug transporters are an important factor in determin-
ing drug and chemical toxicity and hepatocytes express a 
range of these transporters (Funk, 2008). A  quantitative 
screen of transporters mRNA in B-13 cells, B-13/H cells, 
and rat liver showed that the differentiation of B-13 cells to 
B-13/H cells was associated with a general upregulation of 
all 23 transporter mRNAs, although many were expressed 
at levels lower than those seen in adult rat liver (Fig. 8A). 
Figure  8B shows that treatment of B-13/H cells with tro-
glitazone, which inhibits bile salt exporter pump (BSEP) 
function (Funk et al., 2001), caused a significant retention 
of CLF, indicating that the B-13/H cells expressed func-
tional BSEP. Treatment of both B-13 and B-13/H cells with 
the p-glycoprotein inhibitor cyclosporine A  (Nooter et  al., 
1990) or breast cancer resistance protein (BCRP) inhibitor 
KO143 (Allen et  al., 2002) caused a significant retention 
of Hoechst 33342, which is a substrate for both p-glyco-
protein and BRCP (Bunting et al., 1999; Zhou et al., 2001) 
(Fig.  8B). These data suggest that both B-13 and B-13/H 
Fig. 6. RT-PCR screens for phase II gene expression. RT-PCR for GST, SULT (and the generator of the cosubstrate PAPSS), and UDPGT transcripts. 
RT-PCR was performed as outlined in Materials and Methods section using primers as outlined in Table 1. Abbreviations: GST, glutathione S transferase; PAPSS, 
3′-phosphoadenosine-5′phosphosulfate synthase; RT-PCR, reverse transcriptase-PCR; SULT, sulfotransferase; UDPGT, glucuronyltransferase.
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cells express functional p-glycoprotein and BCRP. The mul-
tidrug resistance-associated protein (MRP) inhibitor MK57 
(Leier et al., 1994) caused a significant retention of CMFDA 
in B-13/H cells—but not B-13 cells—indicating that B-13/H 
cells expressed functional MRP transporters (Roelofsen 
et al., 1997).
DisCUssioN
The data in this paper support previous work showing that 
B-13 cells differentiate into hepatocyte-like B-13/H cells in 
response to glucocorticoid treatment (Marek et al., 2003; Shen 
et  al., 2000; Wallace et  al., 2010c). The data extend these 
Fig. 7. Effect of EGF treatment on DNA synthesis in B-13 and B-13/H cells. A, Immunofluorocytochemical staining for BrdU and DNA (DAPI) in B-13 and 
B-13/H cells. Where indicated, B-13 cells were treated with 100 ng/ml EGF for 4 days. BrdU at 15µM was added to culture media 16 h prior to fixation and analysis. 
B, Quantification of the percentage of cell nuclei (DAPI) positive for BrdU. Note, although B-13/H cells accumulated BrdU, this was not significantly accumulated 
into their nuclei. Data are the mean and SD of 3 separate experiments from the same experiment typical of at least 3 separate experiments. *Significantly different 
from vehicle-only-treated cells. Abbreviations: BrdU, bromodeoxyuridine; DAPI, 4′,6-diamidino-2-phenylindole; EGF, epidermal growth factor.
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Fig. 8. B-13 cells upregulate expression of functional transporter genes in B-13/H cells. A, Drug transporter expression in B-13, B-13/H, and control rat liver 
assessed by quantitative RT-PCR. Fold change in transcripts is expressed relative to B-13 cells after normalization to the housekeeping genes ribosomal protein 
large P1, hypoxanthine phosphoribosyltransferase 1, ribosomal protein L13A, lactate dehydrogenase A, and β-actin. B, Efflux assays for BSEP, p-glycoprotein, 
MRP1-6, and ABCG2 in B-13 and B-13/H cells, performed as described in Materials and Methods section. Data are mean and SD of 3 separate determinations 
from the same experiment, typical of 4 separate experiments. *Significantly different from control cells. Abbreviations: BCRP, breast cancer resistance protein; 
BSEP, bile salt export pump; MRP, multidrug resistance-associated protein; RT-PCR, reverse transcriptase-PCR.
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observations (for summary, see Table 2) to show that a male 
pattern of CYP is expressed in B-13/H cells and that the regula-
tion of the major subfamilies of xenobiotic-metabolizing CYPs 
remains essentially intact. Furthermore, this paper demonstrates 
for the first time that transporter gene expression is increased in 
B-13 cells when they are converted to B-13/H cells, such that 
functional transport activity is detectable.
Recent work from this laboratory has demonstrated using 
PCR-based approaches, cytogenetics, and fluorescent in situ 
hybridization techniques that the B-13 cell was derived from 
TABle 2
overview of B-13/H Cell Utility in Toxicity and genotoxicity studies
Cell Phenotype
CommentB-13 B-13/H
Constitutive hepatic CYP450 expression  
and associated activity
 CYP2E1 − +
 CYP2C6 − +
 CYP2C11 − + Male-specific isoform
 CYP2C12 − + (low) Female-specific isoform
 Methapyrilene toxicity No toxicity Toxicity Toxicity dependent of CYP2C11  
(Ratra et al., 1998)
Phase II expression
 SULTs 3/14 genes expressed. 5/14 genes expressed. 11/14 genes expressed in liver.
 UDPGTs 2/8 hepatic genes expressed. 5/8 hepatic genes expressed. 8/8 genes detectable in liver.
 GSTs 8/21 genes expressed. 15/21 genes expressed. 18/21 genes detectable in liver.
CYP1A family expression and activity
 AhR expression + +
 CYP1A1 expression + +
 CYP1A2 expression − − Genes disrupted in B-13 cells.
 CYP1B1 expression + −
 AhR-dependent CYP1A1 induction (β-NF) Induction Induction
 EROD activity induction (β-NF) Induction Induction
 Benzo[α]pyrene genotoxicity @ 100µM @ 25µM and higher
CYP2B family expression and activity
 CAR expression − +
 CYP2B1 expression − +
CAR-dependent CYP2B1 induction  
(PB, TCPOBOP, DEX)
None Induction Restricted to mRNA induction.
 PROD activity induction (PB) None None Very low levels of increase with PB and 
DEX, likely associated with other 
P450s. CYP2B translation appears to be 
absent in B-13/H cells.
 Cyclophosphamide genotoxicity − − Observed at 200µM in B-13/H cells only—
likely associated with activation by other 
CYPs
CYP3A family expression and activity
 PXR expression − +
 CYP3A1 expression − +
 CYP3A2 expression − +
PXR-dependent CYP3A1 induction  
(PB, DEX, PCN)
None Induction
Luciferin-IPA activity induction  
(PB, DEX, PCN)
None Induction
 Aflatoxin B1 genotoxicity None* @ at least 100nM after 
 induction with DEX.
*Treatment of B-13 cells with inducing 
high levels of DEX likely resulted in 
partial differentiation of cells to B-13/H 
cells.
Transporter function
 Abcb11 (BSEP) None Detectable
 Abcb1b (p-glycoprotein) Detectable Detectable
 Abcc (MRP1-6) Detectable Detectable
 Abcg2 (BCRP) Detectable Detectable
−, no/low expression; +, expressed.
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a male rat (Fairhall et al., 2013a). The data in this paper show 
that when converted to B-13/H cells, the major male-specific 
CYP2C11 gene is expressed at levels at least 100 times higher 
than the major female-specific CYP2C12 gene. These data sug-
gest that the B-13/H cell has maintained to a significant degree, 
the sexually dimorphic hepatic expression of CYPs.
The sexual dimorphism of several hepatic CYPs has been 
shown to be regulated by neonatal sex hormone imprinting the 
cyclical growth hormone secretion from the pituitary (Morgan 
et  al., 1985; Sharma et  al., 2012; Waxman and Holloway, 
2009). Thus, in vivo, it is thought that the distinct male and 
female cyclical serum growth hormone patterns give rise to the 
pattern of expression of the male (eg, CYP2C11) and female 
forms (eg, CYP2C12). CYP2C11 is the major hepatic CYP 
in male rat liver and is reported to be specifically expressed 
in the liver (Thangavel et al., 2007). In our hands, CYP2C11 
mRNA was not detectable in pancreas, spleen, heart, brain, or 
lung. Only the kidney expressed detectable levels of CYP2C11 
mRNA, at < 1% of hepatic levels as determined by quantitative 
RT-PCR (data not shown). Expression of the CYP2C11 pro-
tein at levels similar to male rat liver and the potent toxicity of 
methapyrilene in B-13/H cells serve to emphasize the quantita-
tive nature of conversion that occurs as B-13 cells differentiate 
into B-13/H cell.
The data in this paper suggest that there may be an additional 
epigenetic mechanism of regulation of CYP at the level of the 
liver because growth hormone levels in culture (present within 
the serum component of the culture medium) were not modu-
lated into a cyclical concentration pattern to mimic the male rat 
pattern observed in vivo. Remarkably, despite being generated 
at least 18 years ago (Mashima et al., 1996), B-13 cells have 
retained this epigenetic control of CYP2C11 expression. B-13 
cells may therefore be an important tool with which to inves-
tigate this aspect of sexually dimorphic expression of hepatic 
gene expression.
In terms of screening for drug and chemical toxicity and gen-
otoxicity, B-13/H cells may have considerable utility given their 
ease of use. Both B-13 and B-13/H cells expressed CYP1A1 
and B-13/H cells responded similarly to rat hepatocytes with 
respect to AhR-dependent induction of CYP1A1, resulting in 
functional CYP1A1 protein expression. Accordingly, dose-
dependent increases in DNA damage were detectable in B-13/H 
cells after exposure to benzo[α]pyrene, after pretreatment with 
the AhR agonist β-NF.
B-13/H cells expressed low levels of CAR and induced the 
CAR-responsive gene CYP2B1 to high levels in response to 
treatment with CAR activators in a manner more qualitatively 
reflective of the rat liver in vivo than primary rat hepatocytes. 
However, functional CYP2B activity was low and increased 
minimally by CAR activator treatment, with only relatively 
high concentrations of cyclophosphamide capable of induc-
ing DNA damage in B-13/H cells. Culturing B-13/H cells on 
collagen or collagen sandwiches, which have been reported 
to potentiate CYP2B induction response in primary rat 
hepatocytes (De Smet et al., 2001; Kocarek et al., 1994), did 
not result in a more effective functional CYP2B induction (data 
not included), and therefore the reason why CYP2B1 mRNA 
was not efficiently translated into functional protein is currently 
unclear. One potential explanation could be that the CYP2B 
induction response is more sensitive to limited heme availa-
bility (Acharya et al., 2010), although we have demonstrated 
that B-13/H cells synthesize heme and are capable of gener-
ating CYP spectrophotometrically detectable in its reduced 
state when bound with carbon monoxide (which requires heme 
incorporation) (Fairhall et al., 2013a). Thus, under the culture 
conditions employed, B-13 cells remain limited in their abil-
ity to identify CYP2B-dependent toxicity and genotoxicity. 
However, they may be a tractable model in which to study the 
mechanism of CYP2B induction at the transcriptional level. 
B-13 cells may also be an effective model system in which to 
identify regulators of CYP2B translation.
B-13/H cells expressed PXR and induced the PXR-
responsive gene CYP3A1 gene to high levels in response to 
treatment with PXR activators. In contrast to CYP2B enzymes, 
CYP3A enzymes were significantly functional and activated 
aflatoxin B1 to a DNA-damaging species.
Gene expression associated with phase II metabolism was 
also examined in B-13 and B-13/H cells. RT-PCR screening 
suggests that the expression of a number of genes is increased 
as the B-13 cells transdifferentiate into B-13/H cells. However, 
it remains to be seen whether these changes result in the expres-
sion of functional phase II activity. Overall, however, the data 
suggest that B-13/H cells may be a valuable and readily appli-
cable model for studying and/or screening for hepatoxicity. In 
terms of genotoxicity, B-13/H cells may be limited to comet 
assays (albeit limited currently to CYP1A- and CYP3A-
activated compounds). As observed with primary rat hepato-
cytes, B-13/H cells appear to be refractive to mitogens in 
culture, although the reasons for this remain unclear because 
hepatocytes readily undergo mitosis in vivo (Wallace et  al., 
2010a). However, if proliferation can be induced in B-13/H 
cells, then B-13/H cells may also be suitable for testing chemi-
cals for clastogenicity.
Transporters play a key role in determining the toxicity of 
drugs and chemicals, although their study has been limited 
because their expression is rapidly lost in primary hepatocytes 
(Borlak and Klutcka, 2004; Tchaparian et al., 2011). Functional 
studies are also limited by the fact that transporter expression 
is localized to different membrane compartments of the hepato-
cyte. In vivo, the hepatocyte is polarized and this is challenging 
to replicate in vitro and may impact on transporter expression 
and function.
B-13/H cells upregulated the expression of all transporter 
mRNAs (relative to B-13 cells) and expressed several at lev-
els similar to the liver in vivo. However, many transporters 
were expressed at low levels in B-13/H cells compared with 
those seen in vivo. For example, BSEP and Na+-taurocholate 
cotransporting polypeptide—transporters involved in the 
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efflux and influx of bile acids, respectively—were poorly 
expressed in both B-13 and B-13/H cells. Although several 
transporters were expressed at relatively low levels in B-13/H 
cells, efflux assays indicated that the transporters were detect-
ably functional in these cells. The accessible 2 dimensional 
culture system employed in these studies may not be optimal 
for all hepatic functions. Sandwich culture has been shown to 
promote the formation of bile canaliculi (Swift et al., 2010) 
and may therefore enhance transporter function in B-13/H 
cells. Future studies using 3D culture formats and sandwich 
culture with a variety of extracellular matrix formulations 
may be required to increase transporter gene expression in 
B-13/H cells.
Because B-13 cells are rat cells, species differences could 
limit extrapolation of toxicity data to man. However, introduc-
tion of human drug-metabolizing enzymes and drug transport-
ers could be used to humanize the line. The humanization of 
B-13 cells with human CYP1A2 demonstrates proof of concept 
that the B-13 cell line can be readily modified in this way.
To our knowledge, the generation from a progenitor or stem 
cell of hepatocyte-like cells with functions in many cases at a 
quantitatively similar to levels in primary hepatocytes has not 
been demonstrated for any other cell line, with the exception 
of HepRG cells (Andersson, 2010). Given the simple culture 
conditions and the requirement for a single hormone treatment 
to convert B-13 cells to B-13/H cells, B-13 cells will have con-
siderable utility in the study of hepatotoxicity and genotoxicity 
studies. Furthermore, the replacement of primary hepatocytes 
with B-13/H cells would significantly reduce the number of 
animals used for hepatocyte generation.
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